Jun 03, 2021
Lundbeck to Showcase New VYEPTI® (eptinezumab-jjmr) Data at 63rd Annual Scientific Meeting of the American Headache Society (AHS)
Lundbeck today announced that new data on migraine prevention with VYEPTI® (eptinezumab-jjmr) will be presented at the 63rd Annual Scientific Meeting of the American Headache Society (AHS), taking place virtually from June 3-6, 2021.
Apr 20, 2021
New Data Presented at 2021 American Academy of Neurology (AAN) Annual Meeting Shows VYEPTI® (eptinezumab-jjmr) Demonstrated Earlier Time to Freedom from Headache Pain and Absence of Most Bothersome Symptoms Compared to Placebo When Initiated During Migraine Attack in Patients Who Were Candidates for Preventive Therapy
Lundbeck today announced new data from two abstracts for VYEPTI® (eptinezumab-jjmr), presented at the 2021 American Academy of Neurology (AAN), which is being held virtually from April 17 – 22.